| 000 | 01223 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250515144740.0 | ||
| 264 | 0 | _c20081124 | |
| 008 | 200811s 0 0 eng d | ||
| 022 | _a1532-1827 | ||
| 024 | 7 |
_a10.1038/sj.bjc.6604693 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEveno, C | |
| 245 | 0 | 0 |
_aDid animal offer relevant model for Bevacizumab testing? _h[electronic resource] |
| 260 |
_bBritish journal of cancer _cNov 2008 |
||
| 300 |
_a1555; author reply 1556 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 |
_aHead and Neck Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aGaujoux, S | |
| 700 | 1 | _aTobelem, G | |
| 700 | 1 | _aPocard, M | |
| 773 | 0 |
_tBritish journal of cancer _gvol. 99 _gno. 9 _gp. 1555; author reply 1556 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bjc.6604693 _zAvailable from publisher's website |
| 999 |
_c18433948 _d18433948 |
||